Skip To Main Content
Zhenying Cai on Muck Rack

Zhenying Cai

As seen in: Wiley Online Library, PLOS ONE, BioRxiv, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zhenying

Contact Zhenying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Statin-dye conjugates for selective targeting of KRAS mutant cancer cells

|
By Hye-ran Moon, Zhenying Cai, Hyeyoun Chang, Seung Taek Hong
| PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Citation: Moon H-r, Cai Z, Cho BK, Chang H, Hong ST, Zhao JJ, et al. (2026) Statin-dye conjugates for selective targeting of KRAS mutant cancer cells. PLoS One 21(1): e0340189. https://doi.org/10.1371/journal.pone.0340189 Editor: Luca Pesce, Università di Pisa: Universita degli Studi di Pisa, ITALY Received: April 24, 2025; Accepted: December 17, 2025; Published: January 9, 2026 Copyright: © 2026 Moon et al.
Open in Who Shared Issue with article?

Enhancing the Accuracy of Skin Lesion Diagnosis Using Hyperspectral Imaging and Deep Learning

|
By Huiwen Zheng, Yunqing Ren, Lijuan Yu, Zhenying Cai
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. References 1, , and , “Psoriasis: A Brief Overview,” Clinical Medicine 21, no. 3 (2021): 170–173. 2, , , , , and , “Actinic Keratosis: Current Challenges and Unanswered Questions,” Journal of the European Academy of Dermatology and Venereology 38 (2024): 3–11. 3, , , et al., “Seborrheic Keratosis,” JDDG: Journal of the German Society of Dermatology 21, no. 3 (2023): 265–277. 4, , and , “Dermatoscopy,” Clinics in Dermatology 39, no.
Open in Who Shared Issue with article?

Statin-dye conjugates for selective targeting of KRAS mutant cancer cells

|
By Hye-ran Moon, Zhenying Cai, Hyeyoun Chang, Seung Taek Hong
| BioRxiv
Abstract Over 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve KRAS mutations (KRASMUT), for which current treatment options are limited. Statins, commonly used to lower cholesterol, have demonstrated certain selective toxicity towards KRAS-transformed cells, prompting the question of whether statins could achieve selective uptake specifically in KRASMUT cells.
Open in Who Shared Issue with article?
See all 6 articles